Minocycline safety and tolerability in Huntington disease.
about
Therapeutic interventions for symptomatic treatment in Huntington's diseaseEvidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of NeurologyReversal of a full-length mutant huntingtin neuronal cell phenotype by chemical inhibitors of polyglutamine-mediated aggregationMouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II.Neuroimmunology of Huntington's Disease: Revisiting Evidence from Human StudiesInterrater agreement in the assessment of motor manifestations of Huntington's disease.A futility study of minocycline in Huntington's disease.Use of minocycline in viral infectionsProspects for minocycline neuroprotection.Emerging chemotherapeutic strategies for Huntington's disease.The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies.A systematic review of the treatment studies in Huntington's disease since 1990.Huntington's disease: progress and potential in the field.Minocycline protects motor but not autonomic neurons after cauda equina injury.Emerging drug therapies in Huntington's disease.Huntington's disease: can mice lead the way to treatment?The most appropriate primary outcomes to design clinical trials on Huntington's disease: meta-analyses of cohort studies and randomized placebo-controlled trials.Advancing pharmacotherapy for treating Huntington's disease: a review of the existing literature.MR-spectroscopic findings in juvenile-onset Huntington's disease.Revisiting safety of minocycline as neuroprotection in Huntington's disease.A pilot, open-label, 8-week study evaluating the efficacy, safety and tolerability of adjunctive minocycline for the treatment of bipolar I/II depression.Results of a phase II placebo-controlled randomized trial of minocycline in acute spinal cord injury.Rating Scales and Performance-based Measures for Assessment of Functional Ability in Huntington's Disease: Critique and Recommendations
P2860
Q24239893-DE34BF00-BAAB-4F62-9925-43C6311279EBQ24621818-504DCA01-11D9-43C5-B50E-06930B904D01Q24799882-55A6CC5A-5309-4972-A59F-7722659C53C0Q27005950-9A913CF2-82B5-4DCD-980A-39B78D95F5C6Q28072237-E4056BAB-E941-4BA1-B9BF-C50447243A28Q33209649-B66A2137-4F58-47E6-B400-7539F175FC0CQ34622616-9A701AEB-C727-4130-8896-F6E7B54BEA72Q35062807-0F41F2CC-3F8C-4933-A4DB-F400C98FE84BQ35079515-D566CA3A-C7A8-4D4E-B004-09324F1C76C2Q36150628-02286CE5-D4E0-4283-8DB7-7916F21F17A8Q36358871-3654590A-B6B0-4634-A783-CA9B306AAD1AQ36719669-BEA64761-9510-43BB-9AC5-5ED3FCC0B41DQ37016096-040F59CC-6901-46EE-903F-1ADA694B75F9Q37216519-9381342D-DFEF-427F-BA70-1F28F06D251AQ37488273-BE02624F-C402-428B-B104-93B76EBBA375Q37840353-ED4AD049-D36B-42D7-8B77-054C6E20C6AAQ38202178-AE4C5491-E927-4135-9EF2-CC9097C0230DQ38624994-DE6820DB-7AD3-4AF3-820D-80575494A92DQ45290725-53A9C117-011D-403F-9199-90AFC347D417Q45303074-14C42565-0C56-48C0-9CF3-D54088947718Q47861374-99D907BA-A6AF-4D7E-9C50-DD528B151978Q48566899-FA26EE20-F717-430E-A0B4-FFC57208AED3Q58574520-2F6EEB0C-2251-465D-966A-CAB76B7C97A1
P2860
Minocycline safety and tolerability in Huntington disease.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Minocycline safety and tolerability in Huntington disease.
@en
Minocycline safety and tolerability in Huntington disease.
@nl
type
label
Minocycline safety and tolerability in Huntington disease.
@en
Minocycline safety and tolerability in Huntington disease.
@nl
prefLabel
Minocycline safety and tolerability in Huntington disease.
@en
Minocycline safety and tolerability in Huntington disease.
@nl
P1433
P1476
Minocycline safety and tolerability in Huntington disease.
@en
P2093
Huntington Study Group
P304
P356
10.1212/01.WNL.0000133403.30559.FF
P407
P577
2004-08-01T00:00:00Z